Strategic Implications If validated in prospective randomized trials, GLP-1 receptor agonists could: Represent an adjunctive strategy in obesity-associated asthma Expand the therapeutic footprint of GLP-1s beyond metabolic disease Influence treatment guidelines in high-BMI asthma populations Given the rapid adoption of GLP-1 therapies globally, further investigation into respiratory benefits could have significant clinical and commercial implications
Whether due to reaching health goals, side effects, or cost concerns, discontinuing the medication can bring questions and challenges
Consumers get creative Many patients told NPR they have been stocking up on compounded tirzepatide
Zepbound (Tirzepatide) Available in Hayward, Zepbound offers a dual-action approach by targeting GLP-1 and GIP hormones
Systems such as Medtronics MiniMed, Insulets Omnipod, and Tandems t:slim X2 with Control-IQ create closed-loop architectures where the insulin, the pump, the sensor, and the algorithm are all potentially separately patentable